kabutan

PRISM BioLab Co.,LTD(206A) Summary

206A
TSE Growth
PRISM BioLab Co.,LTD
172
JPY
-7
(-3.91%)
Dec 5, 12:46 pm JST
1.10
USD
Dec 4, 10:46 pm EST
Result
PTS
outside of trading hours
171.9
Dec 5, 12:46 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.35
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
176 JPY 1.13 USD
Previous Close Dec 4
179 JPY 1.15 USD
High Dec 5, 9:00 am
176 JPY 1.13 USD
Low Dec 5, 10:22 am
166 JPY 1.07 USD
Volume
1,035,500
Trading Value
0.18B JPY 1.14M USD
VWAP
171.0 JPY 1.1 USD
Minimum Trading Value
17,200 JPY 110 USD
Market Cap
6.35B JPY 0.04B USD
Number of Trades
535
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
364
1-Year High Dec 2, 2025
10,028
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 1,909,400
Nov 21, 2025 0 1,893,300
Nov 14, 2025 0 1,555,000
Nov 7, 2025 0 1,596,700
Oct 31, 2025 0 1,517,800
Company Profile
PRISM BioLab Co., LTD engages in the research and development of new drugs using its proprietary drug discovery platform (PepMetics technology).
Sector
Pharmaceuticals
PRISM BioLab is a research and development-oriented venture company focusing on drug discovery utilizing its proprietary PepMetics technology platform. The company is dedicated to creating small molecule drugs targeting intracellular protein-protein interactions (PPIs). By leveraging its unique compound library and synthesis techniques, PRISM BioLab has overcome the challenges associated with traditional approaches, which often resulted in large molecular weight compounds with potential side effects. The company's innovative small molecule compounds have successfully cleared these hurdles, enabling the development of PPI inhibitors. PRISM BioLab has multiple pipelines, including Wnt inhibitors and translation control agents, and pursues both in-house development and collaborative projects with pharmaceutical companies. By pioneering the new drug discovery field of intracellular PPIs, PRISM BioLab aims to create innovative pharmaceuticals for diseases that currently lack effective treatments.